Labcorp to acquire a 15% stake in SYNLAB from Cinven for €140m.

Labcorp, an innovati ve and comprehensive laboratory services company, agreed to acquire a 15% stake in SYNLAB, a medical diagnostic services and specialty testing company, from Cinven, a private equity firm, for €140m. “Our investment in SYNLAB as a minority shareholder provides Labcorp with a role on the co-investors’ holding company board and the commitment to explore possible opportunities in the future to bring Labcorp’s innovative specialty tests to markets in Europe, consider possible procurement collaborations, evaluate opportunities to support advances in clinical trials and enrollment and improve personalized care,” Glenn Eisenberg, Labcorp CFO.